Literature DB >> 11269805

Surgical management of paralytic scoliosis in myelomeningocele.

D Parsch1, F Geiger, D R Brocai, R D Lang, C Carstens.   

Abstract

A retrospective analysis of 54 patients with paralytic scoliosis due to myelomeningocele, who underwent surgical treatment, was performed. The aim of this study was to compare different surgical techniques and to identify clinical parameters influencing primary and midterm results. Three surgical techniques were used: 1) group I, posterior fusion/instrumentation; 2) group II, anterior fusion/no instrumentation combined with posterior fusion/instrumentation; and 3) group III, anterior and posterior fusion/instrumentation. Average age at surgery was 13.1 years. A preoperative scoliosis angle of 90 degrees [interquartile range (25th-75th percentile) (IQR), 76-106 degrees] was primarily reduced to 38 degrees (IQR, 30-50 degrees). At final follow-up (mean, 3.3 years), correction deteriorated to 44 degrees (IQR, 38-65 degrees). The group III procedure resulted in a better midterm correction of scoliosis compared with group I (P = 0.02). The extension of anterior fusion correlated with primary and midterm correction of scoliosis (P < 0.03). Patients with a thoracic level of paralysis had a higher relative loss of correction compared with patients with a lumbar level (P < 0.06). This finding can be attributed mostly to group I patients (P = 0.011). Hardware complications occurred in 16 patients (30%). Relative loss of correction among these patients was high (P < 0.01) and relative midterm correction low (P = 0.001). We recommend anterior and posterior fusion, each with instrumentation for the treatment of paralytic scoliosis in myelomeningocele. In patients with a thoracic level of paralysis, the two-stage procedure is mandatory to reduce the risk of hardware complications and subsequent major loss of correction.

Entities:  

Mesh:

Year:  2001        PMID: 11269805

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  6 in total

1.  Spinal fusion in children with spina bifida: influence on ambulation level and functional abilities.

Authors:  M A G C Schoenmakers; V A M Gulmans; R H J M Gooskens; J E H Pruijs; P J M Helders
Journal:  Eur Spine J       Date:  2004-07-16       Impact factor: 3.134

2.  Surgical treatment of patients with myelomeningocele-related spine deformities: study of 26 cases.

Authors:  Huseyin Canaz; Ibrahim Alatas; Gokhan Canaz; Gurkan Gumussuyu; Mehmet Akif Cacan; Ayten Saracoglu; Bekir Yavuz Ucar
Journal:  Childs Nerv Syst       Date:  2018-01-25       Impact factor: 1.475

3.  The Classification for Early-onset Scoliosis (C-EOS) Correlates With the Speed of Vertical Expandable Prosthetic Titanium Rib (VEPTR) Proximal Anchor Failure.

Authors:  Howard Y Park; Hiroko Matsumoto; Nicholas Feinberg; David P Roye; Wajdi W Kanj; Randal R Betz; Patrick J Cahill; Michael P Glotzbecker; Scott J Luhmann; Sumeet Garg; Jeffrey R Sawyer; John T Smith; John M Flynn; Michael G Vitale
Journal:  J Pediatr Orthop       Date:  2017-09       Impact factor: 2.324

Review 4.  Prevalence of complications in neuromuscular scoliosis surgery: a literature meta-analysis from the past 15 years.

Authors:  Shallu Sharma; Chunsen Wu; Thomas Andersen; Yu Wang; Ebbe Stender Hansen; Cody Eric Bünger
Journal:  Eur Spine J       Date:  2012-10-21       Impact factor: 3.134

5.  Does Kyphectomy Improve the Quality of Life of Patients With Myelomeningocele?

Authors:  Pedro Araujo Petersen; Raphael Martus Marcon; Olavo Biraghi Letaif; Marcus Alexandre Mello Santos; Rafael Garcia Oliveira; Tarcísio Eloy Passos de Barros Filho; Alexandre Fogaça Cristante
Journal:  Clin Orthop Relat Res       Date:  2020-01       Impact factor: 4.755

Review 6.  Orthopedic management of myelomeningocele with a multidisciplinary approach: a systematic review of the literature.

Authors:  Ana Presedo; Amirali Karimi; Parnian Shobeiri; Sara Momtazmanesh; Fardis Vosoughi; Mohammad Hossein Nabian
Journal:  J Orthop Surg Res       Date:  2021-08-13       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.